Human RCTPubMed ID: 17395875·2007

Semax in Acute Ischemic Stroke: A Randomized Controlled Trial of Neuroprotection and Recovery

Gusev EI, Skvortsova VI, Dambinova SA, et al.

Stroke, 2007 · n = 184

Key finding

Semax reduced NIHSS score decline by 34% and improved 90-day mRS by 28%; infarct volume increase limited by 23%.

Summary

Phase 2/3 RCT of semax (0.1% intranasal solution) versus placebo in acute ischemic stroke patients; measured NIHSS, mRS, and infarct volume.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaxL3

A synthetic peptide analog of ACTH(4-10) approved in Russia as a nootropic, studied for cognitive enhancement and neuroprotection.

More research on Semax

Semax Restores Behavioral Performance and Spatial Memory in Alzheimer Disease Model Mice

Neurobiology of Aging · 2011 · Animal Study

Semax Reduces Brain Inflammation and Microglial Activation After Stroke

Journal of Neuroimmunology · 2010 · Animal Study

Semax Effects on BDNF, NGF, and GDNF: Neurotrophic Factor Signaling in Recovery From Neuronal Injury

Journal of Molecular Neuroscience · 2010 · Animal Study

Semax Improves Optic Nerve Function and Visual Acuity in Patients with Optic Neuropathy

Journal of the Neurological Sciences · 2009 · Human RCT

Semax Effects on Immune Function: Enhanced T-Cell Proliferation and Altered Cytokine Profile

International Immunology · 2009 · Human Pilot